Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Mersana Therapeutics Inc (MRSN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 118,450
  • Shares Outstanding, K 23,180
  • Annual Sales, $ 17,550 K
  • Annual Income, $ -38,710 K
  • 36-Month Beta 1.10
  • Price/Sales 7.02
  • Price/Cash Flow N/A
  • Price/Book 4.05

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate -0.70
  • Number of Estimates 6
  • High Estimate -0.65
  • Low Estimate -0.75
  • Prior Year -0.61
  • Growth Rate Est. (year over year) -14.75%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.07 +0.79%
on 12/04/18
6.83 -25.18%
on 11/15/18
-1.74 (-25.40%)
since 11/07/18
3-Month
5.07 +0.79%
on 12/04/18
15.93 -67.92%
on 09/17/18
-8.60 (-62.73%)
since 09/07/18
52-Week
5.07 +0.79%
on 12/04/18
23.96 -78.67%
on 05/29/18
-10.89 (-68.06%)
since 12/07/17

Most Recent Stories

More News
Mersana Therapeutics Appoints Dirk Huebner, M.D., as Chief Medical Officer

Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) targeting cancers in areas of high...

MRSN : 5.11 (-3.77%)
Mersana Therapeutics Announces Third Quarter 2018 Financial Results and Provides Business Updates

XMT-1536 Phase 1 Dose Escalation Ongoing with Data Expected in the First Half of 2019

MRSN : 5.11 (-3.77%)
Mersana Therapeutics Presents Pre-clinical Data at AACR-NCI-EORTC on Two Additional, Proprietary Antibody Drug Conjugate Platforms and a Pre-clinical Update for XMT-1522 in Non-small Cell Lung Cancer

Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) based on its Dolaflexin and other...

MRSN : 5.11 (-3.77%)
Mersana Therapeutics to Present at the Credit Suisse 27th Annual Healthcare Conference

Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) based on its Dolaflexin and other...

MRSN : 5.11 (-3.77%)
Mersana Therapeutics to Host Conference Call Announcing Third Quarter 2018 Financial Results and Business Updates

Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) based on its Dolaflexin(R) and other...

MRSN : 5.11 (-3.77%)
180 Degree Capital Corp. Reports Net Asset Value Per Share of $2.81 as of September 30, 2018; a Decrease of 3.4% From June 30, 2018

180 Degree Capital Corp. (NASDAQ:TURN) ("180" and the "Company"), today reported its financial results as of September 30, 2018. Key results for the quarter and year to date include:

AIRG : 10.99 (-6.47%)
MRSN : 5.11 (-3.77%)
TST : 2.02 (-1.94%)
IOTS : 4.64 (-6.83%)
TURN : 1.97 (+1.55%)
Analysis: Positioning to Benefit within Matrix Service, Mersana Therapeutics, Quorum Health, Canopy Growth, Bristow Group, and Menlo Therapeutics -- Research Highlights Growth, Revenue, and Consolidated Results

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Matrix Service Company (NASDAQ:MTRX),...

MNLO : 5.67 (+2.35%)
BRS : 3.59 (-1.37%)
MRSN : 5.11 (-3.77%)
MTRX : 18.96 (+0.64%)
QHC : 3.88 (-3.24%)
CGC : 31.40 (+3.49%)
Mersana Therapeutics to Present at Upcoming Investor Conferences

Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) based on its Dolaflexin(R) and other...

MRSN : 5.11 (-3.77%)
Mersana Therapeutics Presents New Preclinical Data on XMT-1536 at the International Association for the Study of Lung Cancer (IASLC) 19th World Conference on Lung Cancer

Novel Immunohistochemistry Assay Distinguishes Non-Small Cell Lung Cancer (NSCLC) Subtypes

MRSN : 5.11 (-3.77%)
Mersana Announces FDA Lifts Partial Clinical Hold for XMT-1522

Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) based on its Dolaflexin and other...

MRSN : 5.11 (-3.77%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade MRSN with:

Business Summary

Mersana Therapeutics, Inc. is a biotechnology company. It focused on discovering and developing a pipeline of antibody drug conjugates. The company's product candidates include XMT-1522 and XMT-1536 which are in clinical stage. Mersana Therapeutics, Inc. is based in CAMBRIDGE, United States.

See More

Key Turning Points

2nd Resistance Point 5.51
1st Resistance Point 5.31
Last Price 5.11
1st Support Level 5.00
2nd Support Level 4.88

See More

52-Week High 23.96
Fibonacci 61.8% 16.74
Fibonacci 50% 14.51
Fibonacci 38.2% 12.29
Last Price 5.11
52-Week Low 5.07

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar